Back to Search

Journal article

Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing

Abstract:: Background

The World Health Organization recommends drug-susceptibility testing of Mycobacterium tuberculosis complex for all patients with tuberculosis to guide treatment decisions and improve outcomes. Whether DNA sequencing can be used to accurately predict profiles of susceptibility to first-line antituberculosis drugs has not been clear.

Methods

We obtained whole-genome sequences and associated phenotypes of resistance or susceptibility to the first-line anti...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Allix-Béguec, C., Arandjelovic, I., Bi, L., Clifton, D., Crook, D., Fowler, P., Gibertoni Cruz, A., Golubchik, T., Hoosdally, S., Hunt, M., Iqbal, Z., Lipworth, S., Peto, T., Thwaites, G., Walker, A., Walker, T., Wilson, D., Wyllie, D., Yang, Y., & et al., T. C. R. P. T. I. C. C. (2018). Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. New England Journal of Medicine, 379(15), 1403–1415.

MLA Style

Allix-Béguec, C., et al. “Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.” New England Journal of Medicine, vol. 379, no. 15, Massachusetts Medical Society, 2018, pp. 1403–15.

Chicago Style

Allix-Béguec, C, I Arandjelovic, L Bi, D Clifton, D Crook, P Fowler, A Gibertoni Cruz, et al. 2018. “Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.” New England Journal of Medicine 379 (15): 1403–15.
Tweet
Print

Access Document

Files:: Allexis Beguec et al.,...

(Version of record, pdf, 291.2KB)

Publisher copy:: 10.1056/NEJMoa1800474

Authors

+ Allix-Béguec, C More by this author

Role:

Author

+ Arandjelovic, I More by this author

Role:

Author

+ Bi, L More by this author

Role:

Author

+ Clifton, D More by this author

Institution:

University of Oxford

Division:

MPLS Division

Department:

Engineering Sciences

Role:

Author

+ Crook, D More by this author

Institution:

University of Oxford

Division:

Medical Sciences Division

Department:

RDM

Sub department:

RDM Clinical Laboratory Science

Role:

Author

More authors...

Funding

+ Seventh Framework Programme More from this funder

Grant:

278864

+ Medical Research Council More from this funder

Grant:

200205/Z/15/Z

+ Wellcome Trust More from this funder

Grant:

200205/Z/15/Z

+ National Institute for Health Research More from this funder

Grant:

CL-2015-13-003

French Government More from this funder

More funders...

Bibliographic Details

Publisher:: Massachusetts Medical Society Publisher's website
Journal:: New England Journal of Medicine Journal website
Volume:: 379
Issue:: 15
Pages:: 1403-1415
Publication date:: 2018-10-11
Acceptance date:: 2018-08-15
DOI:: 10.1056/NEJMoa1800474
EISSN:: 1533-4406
ISSN:: 0028-4793

Item Description

Pubs id:: pubs:910678
UUID:: uuid:a4e5c655-51c0-46aa-9d68-cc276b003c70
Local pid:: pubs:910678
Source identifiers:: 910678
Deposit date:: 2018-08-28

Terms of use

Copyright holder:: Massachusetts Medical Society
Copyright date:: 2018
Notes:: Copyright © 2018 Massachusetts Medical Society. All rights reserved. This is the publisher's version of the article made available with permission of the publisher

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Metrics

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP